Literature DB >> 24401834

PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.

Daniella Lowenberg1, Caroline F Thorn, Zeruesenay Desta, David A Flockhart, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24401834      PMCID： PMC4084804          DOI： 10.1097/FPC.0000000000000019

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  27 in total

Review 1.  Metabolism and transport of oxazaphosphorines and the clinical implications.

Authors:  Jing Zhang; Quan Tian; Sui Yung Chan; Shu Chuen Li; Shufeng Zhou; Wei Duan; Yi-Zhun Zhu
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

2.  Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases.

Authors:  You-Jung Shin; Ji-Young Kim; Jei-Won Moon; Rae-Mi You; Jeong-Yeol Park; Joo-Hyun Nam
Journal:  Cancer Res Treat       Date:  2011-12-27       Impact factor: 4.679

3.  Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).

Authors:  T Cerny; S Leyvraz; T von Briel; A Küpfer; R Schaad; S F Schmitz; P Honegger; C Sessa; J Brunner; A V Boddy
Journal:  Ann Oncol       Date:  1999-09       Impact factor: 32.976

4.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

5.  Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard.

Authors:  R Becker; A Ritter; U Eichhorn; J Lips; B Bertram; M Wiessler; M Z Zdzienicka; B Kaina
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

6.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Pharmacogenet Genomics       Date:  2008-06       Impact factor: 2.089

9.  Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-gamma production.

Authors:  M C Kuppner; E Bleifuss; E Noessner; R Mocikat; C von Hesler; C Mayerhofer; R D Issels
Journal:  Clin Exp Immunol       Date:  2008-07-18       Impact factor: 4.330

10.  Acute liver toxicity with ifosfamide in the treatment of sarcoma: a case report.

Authors:  Michelle Cm Cheung; Robin L Jones; Ian Judson
Journal:  J Med Case Rep       Date:  2011-05-13
View more
  5 in total

1.  Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver.

Authors:  Kritika Karri; David J Waxman
Journal:  Toxicol Sci       Date:  2020-04-01       Impact factor: 4.849

2.  Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy.

Authors:  Anna C Virgili Manrique; Juliana Salazar; María Jesús Arranz; Silvia Bagué; Ruth Orellana; Antonio López-Pousa; Paula Cerdà; Isidre Gracia; Katarina Majercakova; Ana Peiró; Laura Trullols; Manuel Fernández; Sandra Valverde; María Jesús Quintana; Olga Bell; Alícia Artigas-Baleri; Ana Sebio
Journal:  J Pers Med       Date:  2022-04-11

3.  Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study.

Authors:  M E Madeleine van der Perk; Linda Broer; Yutaka Yasui; Leslie L Robison; Melissa M Hudson; Joop S E Laven; Helena J van der Pal; Wim J E Tissing; Birgitta Versluys; Dorine Bresters; Gertjan J L Kaspers; Andrica C H de Vries; Cornelis B Lambalk; Annelies Overbeek; Jacqueline J Loonen; Catharina C M Beerendonk; Julianne Byrne; Claire Berger; Eva Clemens; Uta Dirksen; Jeanette Falck Winther; Sophie D Fosså; Desiree Grabow; Monica Muraca; Melanie Kaiser; Tomáš Kepák; Jarmila Kruseova; Dalit Modan-Moses; Claudia Spix; Oliver Zolk; Peter Kaatsch; Jesse H Krijthe; Leontien C M Kremer; Russell J Brooke; Jessica L Baedke; Ron H N van Schaik; John N van den Anker; André G Uitterlinden; Annelies M E Bos; Flora E van Leeuwen; Eline van Dulmen-den Broeder; Anne-Lotte L F van der Kooi; Marry M van den Heuvel-Eibrink
Journal:  Cancers (Basel)       Date:  2021-09-13       Impact factor: 6.639

4.  Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney.

Authors:  Hyoung-Yun Han; Mi-Sun Choi; Seokjoo Yoon; Je-Won Ko; Sang-Kyum Kim; Tae-Won Kim
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

5.  Pharmacokinetic parameters of ifosfamide in mouse pre-administered with grapefruit juice or naringin.

Authors:  Eduardo Madrigal-Bujaidar; Edilberto Pérez-Montoya; Sandra García-Medina; José Melesio Cristóbal-Luna; José A Morales-González; Eduardo Osiris Madrigal-Santillán; Rogelio Paniagua-Pérez; Isela Álvarez-González
Journal:  Sci Rep       Date:  2019-11-12       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.